<?xml version="1.0" encoding="UTF-8"?>
<p id="Par1691">
 <bold>Results:</bold> A total of 731 patients were included, 376 in the pre-MHP and 355 in the post-MHP group. There were no significant differences in age, sex, ISS, PS14 code, injury mechanism and mortality between the two groups. The use of TXA was significantly higher in the post-MHP group (p &lt; 0.001). The median amount of fluids given at the scene and in the ED was significantly higher (1.5 litres versus 1.0 litre) in the pre-MHP group (p &lt; 0.001). A significantly higher number of units of prothrombin complex concentrate (PCC) and fresh frozen plasma (FFP) were given in the post-MHP group in the ED (both p &lt; 0.05). There was no significant difference in the number of units of blood / plasma reduced cells given in the ED between the two groups. Hospital and ICU length of stay were significantly reduced following the introduction of the MHP (both p &lt; 0.001).
</p>
